CAR-T Meeting 2024 | Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies
In this video, Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, briefly discusses why the changing needs for ad-hoc resources for the safe delivery of advanced therapies must be addressed. Managing complications or adverse events arising from novel therapies requires hospital resources, and therapeutic approaches such as CAR T-cell therapy involve ‘living’ drugs that must be appropriately handled prior to administration. As the number of patients receiving advanced therapies increases in Europe, so does the workload in hospitals and centers where care is provided. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BELLICUM PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
BMS/CELGENE: Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
EBMT: Membership on an entity’s Board of Directors or advisory committees
FRESENIUS KABI: Research Funding
KITE/GILEAD: Honoraria, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
JANSSEN PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
JAZZ: Honoraria
MILTENYI BIOTECH: Research Funding
NOVARTIS: Speakers Bureau
SANOFI SA: Speakers Bureau, Honoraria, Research Funding
TERUMO BCT: Speakers Bureau.
